Stocks Comparison
Colgate Palmolive vs EDGEWELL PERSONAL CARE: revenue, profit, margins and growth compared
Colgate Palmolive brought in $20.4B of revenue in fiscal 2025, EDGEWELL PERSONAL CARE $2.2B in fiscal 2025. Revenue changed by +1.4% at Colgate Palmolive and -1.3% at EDGEWELL PERSONAL CARE on the year before, so Colgate Palmolive grew faster. Colgate Palmolive kept 10.5% of its revenue as net profit, EDGEWELL PERSONAL CARE 1.1%. Free cash flow was $3.6B at Colgate Palmolive and $41.4M at EDGEWELL PERSONAL CARE.
Side by side, latest fiscal year
| CL | EPC | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (September 30, 2025) |
| Revenue | $20.4B | $2.2B |
| Revenue growth | +1.4% | -1.3% |
| Net income | $2.1B | $25.4M |
| Net margin | 10.5% | 1.1% |
| Free cash flow | $3.6B | $41.4M |
| Free cash flow margin | 17.8% | 1.9% |
| Earnings per share (diluted) | $2.63 | $0.53 |
| Cash | $1.3B | $225.7M |
| Debt | $7.8B | $1.4B |
| Price to earnings | 32.7 | 52.5 |
| Market value | $68.6B | $1.3B |
| Dividend yield | 2.42% | n/a |
| Rank by revenue in sector | #58 of 778 · Consumer discretionary | #339 of 778 · Consumer discretionary |
Over the years
Questions about Colgate Palmolive and EDGEWELL PERSONAL CARE
Which is bigger by revenue, Colgate Palmolive or EDGEWELL PERSONAL CARE?
Colgate Palmolive is bigger by revenue: $20.4B in fiscal 2025, against $2.2B for EDGEWELL PERSONAL CARE in fiscal 2025.
Which keeps more of its revenue as profit, Colgate Palmolive or EDGEWELL PERSONAL CARE?
Colgate Palmolive had a net margin of 10.5% in fiscal 2025; EDGEWELL PERSONAL CARE had 1.1% in fiscal 2025.
Which grew revenue faster, Colgate Palmolive or EDGEWELL PERSONAL CARE?
In their latest fiscal years revenue changed by +1.4% at Colgate Palmolive and -1.3% at EDGEWELL PERSONAL CARE.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.